PMC:7228307 / 2443-2736 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T13","span":{"begin":4,"end":12},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"en\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T31","span":{"begin":274,"end":275},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"en\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of "}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T17","span":{"begin":28,"end":40},"obj":"Sentence"},{"id":"T18","span":{"begin":41,"end":176},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"en\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of "}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T13","span":{"begin":4,"end":12},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"en\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of "}

{"project":"LitCovid-sentences","denotations":[{"id":"T17","span":{"begin":28,"end":40},"obj":"Sentence"},{"id":"T18","span":{"begin":41,"end":176},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"en\" antibody therapeutics.\n\nIntroduction\nThe regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of "}